TKPHF - Takeda's MM Data And Other News: The Good Bad And Ugly Of Biopharma
Takeda Reports Positive Data for Late Stage Multiple Myeloma Trial
Takeda Pharmaceutical Company Limited (TAK) announced data from its Phase 3 clinical trial of single-agent oral NINLARO as well as from the US MM-6 study. NINLARO, in combination with lenalidomide and dexamethasone, is currently approved for treating relapsed or refractory multiple myeloma in more than 65 countries.
The phase 3 TOURMALINE-MM4 aims as assessing NINLARO as a standalone first line maintenance therapy in MM patients who have not been given stem cell transplant. The study met its primary endpoint of showing statistically significant improvement in